A CU research team led by Dr. Rebecca Schweppe, Ph.D., have generated two human thyroid cancer cells lines that serve as valuable models to study thyroid cancer biology. The first cell line, TPC-1, contains the RET/PTC-1 rearrangement, which is a common genetic alteration in thyroid papillary carcinomas. The second cell line, MZ-CRC-1, was derived from a patient with medullary thyroid cancer and contains the RET M918T genetic driver mutation. Importantly, these two cell lines have been genetically validated by next-generation sequencing and transcriptome analysis. Thus, the TPC-1 and MZ-CRC-1 cell lines can be used for preclinical studies focused on mechanisms of thyroid cancer.
Landa I, Pozdeyev N, Korch C, et al. Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies. Clin Cancer Res. 2019. pii: clincanres.2953.2018. doi: 10.1158/1078-0432.CCR-18-2953.